JP7337086B2 - スルファメート結合を有するｓｔｉｎｇモジュレーター化合物、及び製造及び使用の方法 - Google Patents

スルファメート結合を有するｓｔｉｎｇモジュレーター化合物、及び製造及び使用の方法 Download PDF

Info

Publication number
JP7337086B2
JP7337086B2 JP2020550712A JP2020550712A JP7337086B2 JP 7337086 B2 JP7337086 B2 JP 7337086B2 JP 2020550712 A JP2020550712 A JP 2020550712A JP 2020550712 A JP2020550712 A JP 2020550712A JP 7337086 B2 JP7337086 B2 JP 7337086B2
Authority
JP
Japan
Prior art keywords
purin
fluoro
compound
mmol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020550712A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518400A5 (https=
JPWO2019180683A5 (https=
JP2021518400A (ja
Inventor
ジェフリー シャバーリ，
ディラン ブラッドリー イングランド，
ケネス エム． ギグスタッド，
アレクサンドラ イー． ゴールド，
ポール グリーンスパン，
ヨンボ フー，
シー－チュン ファン，
スティーブン ポール ラングストン，
尋丈 水谷
ジャン シー，
シュテファン ヴィスコシル，
へ シュー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2021518400A publication Critical patent/JP2021518400A/ja
Publication of JP2021518400A5 publication Critical patent/JP2021518400A5/ja
Publication of JPWO2019180683A5 publication Critical patent/JPWO2019180683A5/ja
Application granted granted Critical
Publication of JP7337086B2 publication Critical patent/JP7337086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020550712A 2018-03-23 2019-03-22 スルファメート結合を有するｓｔｉｎｇモジュレーター化合物、及び製造及び使用の方法 Active JP7337086B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862647227P 2018-03-23 2018-03-23
US62/647,227 2018-03-23
US201962821831P 2019-03-21 2019-03-21
US62/821,831 2019-03-21
PCT/IB2019/052364 WO2019180683A1 (en) 2018-03-23 2019-03-22 Sting modulator compounds with sulfamate linkages, and methods of making and using

Publications (4)

Publication Number Publication Date
JP2021518400A JP2021518400A (ja) 2021-08-02
JP2021518400A5 JP2021518400A5 (https=) 2022-03-29
JPWO2019180683A5 JPWO2019180683A5 (https=) 2022-03-29
JP7337086B2 true JP7337086B2 (ja) 2023-09-01

Family

ID=66397323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550712A Active JP7337086B2 (ja) 2018-03-23 2019-03-22 スルファメート結合を有するｓｔｉｎｇモジュレーター化合物、及び製造及び使用の方法

Country Status (4)

Country Link
US (2) US20210015915A1 (https=)
EP (2) EP3768685A1 (https=)
JP (1) JP7337086B2 (https=)
WO (1) WO2019180683A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912074PA (en) 2016-03-18 2020-02-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
JP7195317B2 (ja) 2017-11-10 2022-12-23 武田薬品工業株式会社 Ｓｔｉｎｇ調節剤化合物、ならびに製造及び使用する方法
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
AU2021377229A1 (en) * 2020-11-11 2023-06-29 Biogen Ma Inc. Oligonucleotides, reagents and preparation thereof
PE20242344A1 (es) 2021-05-12 2024-12-16 Boehringer Ingelheim Int DERIVADOS DE PIRIDINA CON SUSTITUYENTES CICLICOS LIGADOS A N COMO INHIBIDORES DE cGAS
CN120344538A (zh) * 2022-11-09 2025-07-18 勃林格殷格翰国际有限公司 作为cGAS抑制剂的环状吡啶衍生物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
WO2016096174A1 (en) 2014-12-16 2016-06-23 Invivogen Fluorinated cyclic dinucleotides for cytokine induction
JP2017518302A (ja) 2014-06-04 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド
WO2017161349A1 (en) 2016-03-18 2017-09-21 Immune Sensor, Llc Cyclic di-nucleotide compounds and methods of use
WO2019118839A1 (en) 2017-12-15 2019-06-20 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
SG11201610476VA (en) 2014-07-01 2017-01-27 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of sumo activating enzyme
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
CR20180101A (es) 2015-08-13 2018-04-12 Merck Sharp & Dohme Compuestos di-nucleóticos cíclicos como agonistas de sting
CA3002236A1 (en) 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物
US20180369268A1 (en) 2015-12-16 2018-12-27 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
RS67188B1 (sr) 2016-01-11 2025-10-31 Innate Tumor Immunity Inc Ciklični dinukleotidi za lečenje stanja povezanih sa aktivnošću sting kao što je kancer
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
JP2017518302A (ja) 2014-06-04 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド
WO2016096174A1 (en) 2014-12-16 2016-06-23 Invivogen Fluorinated cyclic dinucleotides for cytokine induction
WO2017161349A1 (en) 2016-03-18 2017-09-21 Immune Sensor, Llc Cyclic di-nucleotide compounds and methods of use
WO2019118839A1 (en) 2017-12-15 2019-06-20 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists

Also Published As

Publication number Publication date
EP4242212A3 (en) 2023-11-15
EP4242212A2 (en) 2023-09-13
US20250262298A1 (en) 2025-08-21
EP3768685A1 (en) 2021-01-27
JP2021518400A (ja) 2021-08-02
WO2019180683A1 (en) 2019-09-26
US20210015915A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
JP7337086B2 (ja) スルファメート結合を有するｓｔｉｎｇモジュレーター化合物、及び製造及び使用の方法
US12054512B2 (en) Sting modulator compounds, and methods of making and using
JP7792036B2 (ja) Ｍｃｌ－１阻害剤
TW202513571A (zh) 吡啶并[4,3-d]嘧啶化合物
CN102711766B (zh) N-9-取代的嘌呤化合物、组合物和使用方法
JP7384535B2 (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
TWI784213B (zh) 雜環化合物
US9663525B2 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
TW201825509A (zh) 環狀二核苷酸
TW202332429A (zh) 治療性化合物及其使用方法
US10865208B2 (en) ATG7 inhibitors and the uses thereof
AU2024317622A1 (en) Substitued bicyclic heterocyclic yap-tead and/or taz-tead inhibitors
RU2857665C2 (ru) Соединения пиридо[4,3-d]пиримидина
TW202545531A (zh) 氮—喹唑啉化合物之使用方法
KR20260019509A (ko) Gpr68 조절 활성을 갖는 이환식 헤테로아릴아미드
JP2026505789A (ja) がん及びてんかんの治療に使用するための縮合ベンゾアゼピン誘導体
HK40038496B (en) Mcl-1 inhibitors
HK1176556B (en) N-9-substituted purine compounds, compositions and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230724

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230822

R150 Certificate of patent or registration of utility model

Ref document number: 7337086

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150